Exocrine Pancreatic Insufficiency Pipeline Review H1 2017

1
Exocrine Pancreatic Insufficiency Pipeline Review
H1 2017

• Published  June 2017 Single User
  US 2000
• No. of Pages 42 Corporate User US
  6000

www.ReportsandReports.com
Website
2
Exocrine Pancreatic Insufficiency Pipeline Market
Reviews in H1 2017 Report

• Exocrine Pancreatic Insufficiency
  (Gastrointestinal) pipeline guide helps in
  identifying and tracking emerging players in the
  market and their portfolios, enhances decision
  making capabilities and helps to create effective
  counter strategies to gain competitive advantage.
  Exocrine Pancreatic Insufficiency
  (Gastrointestinal) pipeline guide also reviews of
  key players involved in therapeutic development
  for Exocrine Pancreatic Insufficiency and
  features dormant and discontinued projects. The
  guide covers therapeutics under Development by
  Companies /Universities /Institutes, the
  molecules developed by Companies in Phase III,
  Phase II and Preclinical stages are 1, 3 and 1
  respectively.
• Exocrine Pancreatic Insufficiency Pipeline Review
  H1 2017 provides an overview of the Exocrine
  Pancreatic Insufficiency (Gastrointestinal)
  pipeline landscape. Pharmaceutical and Healthcare
  latest Exocrine Pancreatic Insufficiency -
  Pipeline Review H1 2017 provides comprehensive
  information on the therapeutics under development
  for Exocrine Pancreatic Insufficiency
  (Gastrointestinal), complete with analysis by
  stage of development, drug target, mechanism of
  action (MoA), route of administration (RoA) and
  molecule type. The guide covers the descriptive
  pharmacological action of the therapeutics, its
  complete research and development history and
  latest news and press releases.

Access Complete Report at http//www.reportsnr
eports.com/reports/1057937-exocrine-pancreatic-ins
ufficiency-pipeline-review-h1-2017.html.
3
Exocrine Pancreatic Insufficiency Pipeline Market
Reviews in H1 2017 Report

• Exocrine Pancreatic Insufficiency - Companies
  Involved in Therapeutics Development Discussed
  Anthera Pharmaceuticals Inc, Celleron
  Therapeutics Ltd, Cilian AG, Laboratoires Mayoly
  Spindler SAS, Nordmark Arzneimittel GmbH Co KG.
• Exocrine Pancreatic Insufficiency Drug Profiles
  Discussed burlulipase, Cilase, CXD-101,
  liprotamase, MS-1819.
• The guide is built using data and information
  sourced from proprietary databases,
  company/university websites, clinical trial
  registries, conferences, SEC filings, investor
  presentations and featured press releases from
  company/university sites and industry-specific
  third party sources. Additionally, various
  dynamic tracking processes ensure that the most
  recent developments are captured on a real time
  basis.

Get Discount at http//www.reportsnreports.com/con
tacts/discount.aspx?name1057937.
4
Exocrine Pancreatic Insufficiency Pipeline Market
Reviews in H1 2017 Report

• Featured News Press Releases Covered
• 1.May 15, 2017 Anthera Announces First Patient
  Screened in RESULT Pivotal Phase 3 Clinical Study
  of Sollpura
• 2.Apr 11, 2017 AzurRx Provides Update on MS1819
  Phase II Trial
• 3.Dec 21, 2016 AzurRx BioPharma Announces First
  Three Patients Included in Phase IIa Study with
  MS1819-SD for Endocrine Pancreatic Insufficiency.
• 4.Nov 17, 2016 AzurRx BioPharma and
  Mayoly-Spindler Announce Initiation of Phase II
  Clinical Trial of MS1819-SD for Exocrine
  Pancreatic Insufficiency in Chronic Pancreatitis
  Patients
• 5.Jun 28, 2016 Anthera Provides Clinical Program
  Update for Sollpura
• 6.Mar 19, 2015 Anthera Announces 3 Million
  Research Award from Cystic Fibrosis Foundation
  Therapeutics for Development of Sollpura - a
  Novel Enzyme Therapy

Buy a Copy of Report _at_ http//www.reportsnreports.
com/purchase.aspx?name1057937.
5
Exocrine Pancreatic Insufficiency Pipeline Market
Reviews in H1 2017 Report
List of Tables 1.Number of Products under
Development for Exocrine Pancreatic
Insufficiency, H1 2017 2.Number of Products under
Development by Companies, H1 2017 3.Products
under Development by Companies, H1 2017 4.Number
of Products by Stage and Target, H1 2017 5.Number
of Products by Stage and Mechanism of Action, H1
2017 6.Number of Products by Stage and Route of
Administration, H1 2017 7.Number of Products by
Stage and Molecule Type, H1 2017 8.Exocrine
Pancreatic Insufficiency - Pipeline by Anthera
Pharmaceuticals Inc, H1 2017 9.Exocrine
Pancreatic Insufficiency - Pipeline by Celleron
Therapeutics Ltd, H1 2017 10.Exocrine Pancreatic
Insufficiency - Pipeline by Cilian AG, H1
2017 11.Exocrine Pancreatic Insufficiency -
Pipeline by Laboratoires Mayoly Spindler SAS, H1
2017 12.Exocrine Pancreatic Insufficiency -
Pipeline by Nordmark Arzneimittel GmbH Co KG,
H1 2017 13.Exocrine Pancreatic Insufficiency -
Dormant Projects, Discontinued Products H1 2017
5
6
About Us

• ReportsnReports.com is your single source for all
  market research needs. Our database includes
  500,000 market research reports from over 95
  leading global publishers in-depth market
  research studies of over 5000 micro markets.
• We provide 24/7 online and offline support to our
  customers.
• Tel Phone No 1-888-391-5441 E-mail
  sales_at_reportsnreports.com

www.ReportsandReports.com
Website
www.ReportsandReports.com
Website